FI945703A - 3,4,4-trisybstituoitujen piperidinyyli-N-alkyylikarboksylaattien ja välituotteiden valmistus - Google Patents

3,4,4-trisybstituoitujen piperidinyyli-N-alkyylikarboksylaattien ja välituotteiden valmistus Download PDF

Info

Publication number
FI945703A
FI945703A FI945703A FI945703A FI945703A FI 945703 A FI945703 A FI 945703A FI 945703 A FI945703 A FI 945703A FI 945703 A FI945703 A FI 945703A FI 945703 A FI945703 A FI 945703A
Authority
FI
Finland
Prior art keywords
piperidinyl
intermediates
trisysubstituted
preparation
alkyl carboxylates
Prior art date
Application number
FI945703A
Other languages
English (en)
Swedish (sv)
Other versions
FI106455B (fi
FI945703A0 (fi
Inventor
Scott Alan Frank
Douglas Edward Prather
Jeffrey Alan Ward
John Arnold Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI945703A0 publication Critical patent/FI945703A0/fi
Publication of FI945703A publication Critical patent/FI945703A/fi
Application granted granted Critical
Publication of FI106455B publication Critical patent/FI106455B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI945703A 1993-12-08 1994-12-02 Menetelmä kiteisen (alfaS,3R,4R)-4-(3-hydroksifenyyli)-3,4-dimetyyli-alfa-(fenyylimetyyli)-1-piperidiinipropionihappomonohydraatin valmistamiseksi ja kiteiset välituotteet FI106455B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16407493 1993-12-08
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (3)

Publication Number Publication Date
FI945703A0 FI945703A0 (fi) 1994-12-02
FI945703A true FI945703A (fi) 1995-06-09
FI106455B FI106455B (fi) 2001-02-15

Family

ID=22592858

Family Applications (2)

Application Number Title Priority Date Filing Date
FI945703A FI106455B (fi) 1993-12-08 1994-12-02 Menetelmä kiteisen (alfaS,3R,4R)-4-(3-hydroksifenyyli)-3,4-dimetyyli-alfa-(fenyylimetyyli)-1-piperidiinipropionihappomonohydraatin valmistamiseksi ja kiteiset välituotteet
FI20000353A FI106860B (fi) 1993-12-08 2000-02-17 Menetelmä kiteisen dihydraattiyhdisteen valmistamiseksi ja kiteinen välituote

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20000353A FI106860B (fi) 1993-12-08 2000-02-17 Menetelmä kiteisen dihydraattiyhdisteen valmistamiseksi ja kiteinen välituote

Country Status (31)

Country Link
US (1) US5434171A (fi)
EP (3) EP0984004A3 (fi)
JP (2) JP3834075B2 (fi)
KR (1) KR100356239B1 (fi)
CN (2) CN1057294C (fi)
AT (1) ATE200279T1 (fi)
AU (1) AU681198B2 (fi)
BR (1) BR9404842A (fi)
CA (1) CA2137221C (fi)
CO (1) CO4290427A1 (fi)
CZ (1) CZ290559B6 (fi)
DE (1) DE69427017T2 (fi)
DK (1) DK0657428T3 (fi)
ES (1) ES2155844T3 (fi)
FI (2) FI106455B (fi)
GR (1) GR3036136T3 (fi)
HK (1) HK1013826A1 (fi)
HU (1) HUT71489A (fi)
IL (1) IL111843A (fi)
MY (1) MY121543A (fi)
NO (1) NO302884B1 (fi)
NZ (1) NZ270039A (fi)
PE (1) PE41495A1 (fi)
PL (1) PL181734B1 (fi)
PT (1) PT657428E (fi)
RU (1) RU2145958C1 (fi)
SI (1) SI0657428T1 (fi)
TW (1) TW290540B (fi)
UA (1) UA52577C2 (fi)
YU (2) YU82304A (fi)
ZA (1) ZA949584B (fi)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
DK1436012T3 (en) 2001-10-18 2018-01-22 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CA2549730C (en) 2003-12-16 2012-02-14 Nektar Therapeutics Al, Corporation Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
DK1789067T3 (da) * 2004-08-12 2012-08-27 Helsinn Healthcare Sa Anvendelse af væksthormonsekretionsfremkaldere til stimulering af mave-tarm-systemets motilitet
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006265639A1 (en) * 2005-07-01 2007-01-11 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
KR101453107B1 (ko) 2006-04-21 2014-10-27 디에스엠 아이피 어셋츠 비.브이. 오피오이드 수용체 길항제의 용도
CA2670382A1 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PL2565195T3 (pl) 2007-03-29 2015-10-30 Wyeth Llc Obwodowy receptor opioidowy i jego antagoniści oraz ich zastosowania
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
KR101581480B1 (ko) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 (ｒ),(ｒ)-2,2'-비스-메틸날트렉손의 제조법 및 용도
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
SI2506712T1 (sl) 2009-12-04 2019-06-28 Alkermes Pharma Ireland Limited, Derivati morfinana za zdravljenje prevelikega odmerka mamil
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
EP3355885A4 (en) 2015-10-01 2019-04-24 Elysium Therapeutics, Inc. MULTI-SUBUNIT OPIOID PRODRUGS WITH RESISTANCE TO OVERDOSE AND MISUSE
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu

Also Published As

Publication number Publication date
EP0984004A3 (en) 2003-10-15
IL111843A (en) 2000-02-29
AU7917094A (en) 1995-06-15
EP1607387A2 (en) 2005-12-21
CN1121387C (zh) 2003-09-17
CN1111239A (zh) 1995-11-08
RU2145958C1 (ru) 2000-02-27
HUT71489A (en) 1995-11-28
YU49312B (sh) 2005-06-10
EP0657428B1 (en) 2001-04-04
EP0657428A1 (en) 1995-06-14
PT657428E (pt) 2001-07-31
SI0657428T1 (en) 2001-08-31
FI20000353A (fi) 2000-02-17
CZ290559B6 (cs) 2002-08-14
US5434171A (en) 1995-07-18
NO302884B1 (no) 1998-05-04
PE41495A1 (es) 1995-11-28
DE69427017D1 (de) 2001-05-10
ATE200279T1 (de) 2001-04-15
CN1223257A (zh) 1999-07-21
CA2137221C (en) 2011-02-22
RU94042903A (ru) 1996-10-27
EP0984004A2 (en) 2000-03-08
ES2155844T3 (es) 2001-06-01
GR3036136T3 (en) 2001-09-28
KR950017957A (ko) 1995-07-22
FI106455B (fi) 2001-02-15
YU82304A (sh) 2006-03-03
HK1013826A1 (en) 1999-09-10
JP2006070042A (ja) 2006-03-16
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
IL111843A0 (en) 1995-03-15
MY121543A (en) 2006-02-28
PL181734B1 (pl) 2001-09-28
NO944644L (no) 1995-06-09
DK0657428T3 (da) 2001-05-07
YU70294A (sh) 1997-07-31
JPH07215937A (ja) 1995-08-15
PL306068A1 (en) 1995-06-12
ZA949584B (en) 1996-06-03
UA52577C2 (uk) 2003-01-15
CZ299294A3 (en) 1995-10-18
NO944644D0 (no) 1994-12-02
KR100356239B1 (ko) 2002-12-26
CN1057294C (zh) 2000-10-11
CO4290427A1 (es) 1996-04-17
JP3834075B2 (ja) 2006-10-18
TW290540B (fi) 1996-11-11
DE69427017T2 (de) 2001-09-06
FI945703A0 (fi) 1994-12-02
CA2137221A1 (en) 1995-06-09
EP1607387A3 (en) 2007-01-03
NZ270039A (en) 1996-08-27
AU681198B2 (en) 1997-08-21
BR9404842A (pt) 1995-08-08

Similar Documents

Publication Publication Date Title
FI945703A (fi) 3,4,4-trisybstituoitujen piperidinyyli-N-alkyylikarboksylaattien ja välituotteiden valmistus
FI945626A (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
ES2086065T3 (es) Preparacion de tetrahidropiridinas sustituidas.
EP0422523A3 (en) Process for the preparation of cyclic carbonates
AU652099C (en) Alkene intermediates for the production of certain 1,2-dioxetane compounds
AU4153293A (en) Alkene intermediates for the production of certain 1,2-dioxetane compounds
PH24971A (en) N2-thiocylcarbazate compounds and derivatives thereof

Legal Events

Date Code Title Description
MM Patent lapsed